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care organization. Members initiating therapy between January
1, 2004 and June 30, 2004 with one of the following ﬁve AD
regimens were included in the analysis: donepezil, galantamine,
rivastigmine, memantine, or memantine+AChEI (acetyl-
cholinesterase inhibitor) combination. We excluded members
with previous AChEI use or who were not continuously enrolled
throughout the 360-day pre-treatment and 360-day post-treat-
ment initiation periods. Adherence was deﬁned as the total days
supplied (maximum of 360) of the AD medication initiated
divided by the total days in the post-period (360 days). Change
(post-treatment minus pre-treatment) in pharmacy, medical, and
total (pharmacy+medical) costs was analyzed, adjusting for age,
gender, comorbidities (chronic disease score), AD regimen, and
pre-treatment total costs. RESULTS: A total of 2405 members
were newly started on AD therapy; 65% were female and mean
age was 81 years (SD 7.1). Treatment was initiated with
donepezil (62%), memantine (15%), galantamine (11%),
rivastigmine (8%), and memantine+AChEI (6%). Mean adher-
ence to AD therapy was 0.57 (SD 0.36). The adjusted analysis
revealed that a 0.1 adherence rate increase (for example, an
increase in adherence from 0.5 to 0.6) was associated with an
increase of $215 (p < 0.001) in annual pharmacy costs and a
decrease of $783 (p < 0.001) and $568 (p = 0.008) in annual
medical and total health care costs, respectively. CONCLU-
SIONS: An increase in AD therapy adherence is associated with
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OBJECTIVES: To illustrate use of competing risk methodology
for studying risk of discontinuing, switching, or augmenting
medications used to treat bipolar disorders. METHODS: Admin-
istrative claims data (MarketScan®, Medstat) was used to iden-
tify patients with bipolar disorders treated with montherapy
atypical antipsychotics. Patients were followed 12 months to
identify those augmenting (starting second medication class
within 30 days and before any discontinuation), discontinuing
(medications runs out and no reﬁll within 30 days following
expiration of days supply), and switching (patient discontinues
medications and starts different class within 30 days). Because
risks of augmentation, discontinuation, and switching are not
independent, competing risk methods are used to summarize
likelihood of different outcomes. Cumulative incidence functions
are computed as a function of crude hazards for each of the 3
dependent outcomes. Plots of the cumulative incidence functions
provide estimates of the probability of each outcome occurr-
ing by any time point. RESULTS: A total of 787 patients on
monotherapy atypical antipsychotics were identiﬁed. By 6
months 21% of the patients had discontinued, 3% had switched,
56% had augmented, and the remaining 20% remained on their
initial antipsychotic. By one year 29% of the patients had dis-
continued, 4% had switched, 59% had augmented, and 8%
remained unchanged. CONCLUSIONS: Switching and augmen-
tation are outcomes important to study along with discontinua-
tion. Treating these as independent when estimating risk of each
(e.g. with complement of Kaplan-Meier estimates) would give
biased estimates of the marginal probabilities. Cumulative inci-
dence curves provide a means of dynamically seeing the risks of
all three outcomes.
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OBJECTIVE: Patients with Parkinson’s Disease (PD) have
diminished health related quality of life (HRQoL) due to a
number of emotional, functional and physical limitations. We
examined the reliability and validity of the PDQ-39 as both a
discriminant and evaluative instrument for use in Parkinson’s
disease studies. METHODS: We conducted a literature review
using MEDLINE and HealthStar citing the PDQ-39, from
1995–2005 using the terms “Parkinson’s Disease Questionnaire
or PDQ-39” limited to Humans and English language. We
reviewed each publication for evidence supporting the instru-
ment’s reliability face and content validity, construct validity
measured as the correlation of the PDQ-39 responses with other
relevant instruments and clinical measures, and test-retest relia-
bility or intra class correlation coefﬁcients. Discriminant abilities
were evaluated by looking for evidence of signiﬁcance between
PD patients with varying levels of disability. Responsiveness was
evaluated using change scores and established minimally impor-
tant difference (MID). RESULTS: Thirty-nine papers met the
inclusion criteria. Correlation of scales of the PDQ-39 with the
Medical Outcomes Study 36-item Short Form (SF-36) showed
strong correlation (>0.5). Intraclass correlation coefﬁcients for
each domain of the PDQ-39 ranged from 0.67 to 0.96 across
studies. Mean scores for each domain were shown to be signiﬁ-
cantly statistically different (p < 0.01) between PD patients with
Hoehn & Yahr rating I, II, III, and IV. Changes in PDQ-39 scores
were signiﬁcantly correlated with changes in patients’ retrospec-
tive judgments of change (0.25–0.31, p < 0.01), and changes on
the SF-36 (0.25–0.37, p < 0.05), but not with clinical assess-
ments. Two studies calculated a MID for the PDQ-39 which
varied between 5–10 points on the summary index and 2–11
points across domains. CONCLUSION: There is substantial evi-
dence supporting the reliability and validity of the PDQ-39 as a
discriminate instrument, but further research on its usefulness as
an evaluative instrument is warranted to increase our conﬁdence.
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Multiple sclerosis (MS) being a progressive neurological disease
with no cure, lends itself as an important area for health-related
quality of life (HRQOL) research. A number of questionnaires
have been designed to measure HRQOL in MS patients, but no
one measure has been established as a gold standard. The large
number of questionnaires also gives neurologists a range of
choices but limited information on which to base their selection.
In order to determine the relative advantages and disadvantages
of the HRQOL questionnaires, a comparison of their psycho-
metric properties in the same patient population is necessary.
OBJECTIVE: To review the current literature and identify
studies comparing psychometric properties of MS-related QOL
measures within the same patient population. METHODS:
Studies included were those that administered more than one
HRQOL questionnaire in the same group of patients with MS.
The search was restricted to the PUBMED and MEDLINE data-
bases for articles published between 1991 and 2005. RESULTS:
Of almost 30 MS-related QOL questionnaires, psychometric
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properties for only 8 have been compared in 4 different pub-
lished studies. A common comparator in all four studies has been
the Medical Outcomes Survey Short Form (SF-36). Responsive-
ness to change and patient preferences regarding the question-
naires have been compared less frequently. Overall, the Multiple
Sclerosis Impact Scale (MSIS-29) has been shown to perform
better over a range of psychometric properties compared to the
commonly used MSQOL and the Functional Assessment in MS
(FAMS). CONCLUSIONS: MSIS-29 appears to be a psychome-
trically sound measure of QOL in MS. However, owing to the
paucity of psychometric comparisons in the MS literature,
further rigorous head-to-head comparisons of newer as well as
existing questionnaires with MSIS-29 are warranted. Such results
can guide researchers in selecting an appropriate measure for use
in clinical trials as well as routine clinical practice.
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OBJECTIVES: Understanding the real-world effectiveness of
triptans in migraine, a trial was conducted using patient-reported
outcomes to evaluate the beneﬁt of triptan therapy before and
after switching to eletriptan 40mg. METHODS: Physicians
enrolled migraineurs into an open-label treatment-satisfaction
study using web-based data collection technology. Patients’
demographic information, migraine experience, utilization of
health care resources and level of satisfaction with prior migraine
therapy (both prescription and over-the-counter treatments)
were evaluated separately for headache pain relief, speed of pain
relief and ability to return to daily activities. Patients were then
switched to eletripan 40mg and their level of satisfaction across
each outcome domain was measured for three migraine attacks.
RESULTS: Of the 2778 patients enrolled (87.1% female; mean
age, 37.4 years; 83.6% employed; averaged 5.5 attacks per
month lasting a mean duration of 11 hours; 49.9% high health
care utilizers [≥1 headache-related outpatient and/or emergency
room visit per month]), 2303 (82.9%) treated at least one
migraine attack with eletriptan 40mg. Patient-reported satisfac-
tion (4 or 5 on a 5-point scale) with eletriptan 40mg was 68.8%,
57.2% and 62.8% for headache pain relief, speed of pain relief
and ability to return to daily activities, respectively, and was sig-
niﬁcantly greater when compared with satisfaction with prior
therapy (triptan and non-triptan): 29.8%, 22.1% and 21.7%,
respectively (p < 0.001). Seventy percent of high health care uti-
lizers achieved satisfactory-to-completely-satisfactory pain relief
on eletriptan 40mg. Employed patients were signiﬁcantly more
satisﬁed (64.2%) than unemployed patients (56%) with eletrip-
tan 40mg (p < 0.01). CONCLUSION: Increased level of patient
satisfaction on eletriptan when compared with prior therapy
indicates a signiﬁcant unmet need for optimized treatment of
acute migraine in this patient population. Further research is
required to determine whether increased satisfaction is associ-
ated with decreased health care utilization. Such real-world effec-
tiveness data might be useful in formulary decision making and
health care beneﬁt design.
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OBJECTIVES: Determine impact of a worksite disease manage-
ment program (DMP) on work productivity loss among employ-
ees with migraines. METHODS: A total of 712 health risk
assessment questionnaires were distributed to employees of a
medical group (64% response rate), with 180 identiﬁed as
migraineurs using IHS criteria from respondent self-report.
Migraineurs were given a DMP which included: 1) tailored
behavioral print material; 2) headache diary; 3) access to work-
site presentations (“Lunch & Learns”) by a physician on trig-
gers, diagnosis and treatment options, Q&A, and instruction on
completion of the MIDAS (Migraine Disability Assessment); 4)
headache tipsheets and suggestions for web-based resources; and
5) access to worksite physicians for same-day treatment. A
follow-up questionnaire distributed 12 months post-launch
revealed no nonresponse bias between respondents (n = 73) and
nonrespondents (n = 107). The primary dependent measure of
the evaluation was work productivity loss (WPL), which com-
bined absenteeism (full and partial days missed due to headache)
and presenteeism (days worked with headache and self-reported
productivity) during the past four weeks. RESULTS: Only 52%
of migraineurs recalled reading the provided tailored educational
print materials on managing their headaches, 28% reported
attending Lunch & Learn sessions, and 7–13% used other
program components. Mean lost productivity dropped only
slightly from baseline to follow-up (8.3 v 7.3 hours, NS).
However, subgroup analyses revealed the program was effective
in signiﬁcantly (p < 0.05) reducing WPL for employees who 1)
increased their level of conﬁdence to control their headaches
after program exposure (6.7 v. 2.3 hours), and 2) sought medical
care for headaches and used migraine prescription medications
(13.4 v. 4.1 hours). CONCLUSIONS: Overall, the DMP failed
to reduce productivity loss among employees with migraines;
however promising ﬁndings were observed for selected groups.
Future programs need to identify effective strategies to improve
self-conﬁdence in headache management and to engage more
migraineurs in seeking medication attention.
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OBJECTIVES: The objective was to determine whether there
was a signiﬁcant association between Body Mass Index scale
(underweight, normal, overweight, moderate obesity, severe
obesity, and very severe obesity) and national medical expendi-
tures (dependent variable) for persons, 18 to 65 years of age,
controlling for demographics of gender, race, marital status, and
education. METHODS: The database used was the Medical
Expenditure Panel Survey (MEPS) for the year 2002. A two-part
model was used to analyze the association between obesity and
health care expenditures. The ﬁrst part was a logistic regression
or binary model, in which expenditures were either existent or
non-existent. This model was adjusted by the demographic vari-
ables of gender, age, race, marital status, and education. The
second part modelled the relationship between expenditure and
BMI. This model was also adjusted by the study demographics.
Park’s test was performed to determine which distribution family
ﬁt the data. In order to accomplish this a General Linear Model
(GLM) framework was used. RESULTS: Approximately 64% of
the sample was overweight or obese. The rest were normal or
underweight. According to the logistic regression, Body Mass
